Inceptionr LLC purchased a new position in Ventas, Inc. (NYSE:VTR - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 23,963 shares of the real estate investment trust's stock, valued at approximately $1,677,000. Ventas comprises about 0.4% of Inceptionr LLC's portfolio, making the stock its 26th biggest position.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Arbor Capital Management Inc. ADV raised its holdings in shares of Ventas by 0.6% in the 3rd quarter. Arbor Capital Management Inc. ADV now owns 21,716 shares of the real estate investment trust's stock valued at $1,520,000 after purchasing an additional 137 shares in the last quarter. Foundations Investment Advisors LLC grew its stake in shares of Ventas by 3.3% during the third quarter. Foundations Investment Advisors LLC now owns 4,447 shares of the real estate investment trust's stock worth $311,000 after purchasing an additional 144 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in Ventas by 3.8% in the second quarter. Ameritas Investment Partners Inc. now owns 4,260 shares of the real estate investment trust's stock valued at $269,000 after buying an additional 155 shares during the last quarter. Checchi Capital Advisers LLC increased its holdings in Ventas by 3.9% in the third quarter. Checchi Capital Advisers LLC now owns 4,603 shares of the real estate investment trust's stock valued at $322,000 after buying an additional 174 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in Ventas by 4.6% in the third quarter. Parallel Advisors LLC now owns 3,970 shares of the real estate investment trust's stock valued at $278,000 after buying an additional 175 shares in the last quarter. Institutional investors and hedge funds own 94.18% of the company's stock.
Ventas Stock Down 0.0%
VTR opened at $84.94 on Monday. Ventas, Inc. has a one year low of $60.15 and a one year high of $87.87. The company has a debt-to-equity ratio of 1.03, a quick ratio of 0.67 and a current ratio of 0.67. The stock has a market capitalization of $40.34 billion, a P/E ratio of 157.30, a price-to-earnings-growth ratio of 2.07 and a beta of 0.73. The business's 50-day simple moving average is $80.65 and its 200-day simple moving average is $75.81.
Ventas (NYSE:VTR - Get Free Report) last announced its earnings results on Thursday, February 5th. The real estate investment trust reported $0.15 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.89 by ($0.74). The firm had revenue of ($1,229.71) million during the quarter, compared to analyst estimates of $1.53 billion. Ventas had a net margin of 4.31% and a return on equity of 2.09%. The firm's revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period last year, the company earned $0.81 earnings per share. Ventas has set its FY 2026 guidance at 3.780-3.880 EPS. Analysts anticipate that Ventas, Inc. will post 3.4 EPS for the current year.
Ventas Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 16th. Stockholders of record on Tuesday, March 31st will be issued a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This is an increase from Ventas's previous quarterly dividend of $0.48. This represents a $2.08 annualized dividend and a dividend yield of 2.4%. Ventas's dividend payout ratio is currently 355.56%.
Analysts Set New Price Targets
A number of brokerages have issued reports on VTR. Jefferies Financial Group reaffirmed a "buy" rating and set a $93.00 price target on shares of Ventas in a report on Monday, December 15th. KeyCorp raised their target price on Ventas from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Weiss Ratings upgraded Ventas from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Monday, December 29th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $93.00 price target on shares of Ventas in a report on Monday, February 9th. Finally, Mizuho increased their price target on shares of Ventas from $87.00 to $94.00 and gave the company an "outperform" rating in a research note on Wednesday, March 4th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $89.00.
Read Our Latest Research Report on VTR
Insider Transactions at Ventas
In other news, CFO Robert F. Probst sold 29,930 shares of Ventas stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $77.25, for a total value of $2,312,092.50. Following the transaction, the chief financial officer directly owned 138,434 shares of the company's stock, valued at $10,694,026.50. The trade was a 17.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Debra A. Cafaro sold 10,322 shares of Ventas stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $77.66, for a total transaction of $801,606.52. Following the completion of the transaction, the chief executive officer directly owned 1,114,034 shares in the company, valued at $86,515,880.44. The trade was a 0.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 86,106 shares of company stock worth $6,931,397. Insiders own 1.00% of the company's stock.
About Ventas
(
Free Report)
Ventas, Inc NYSE: VTR is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.
Ventas' business model combines property ownership with active asset management and capital markets activity.
Further Reading
Want to see what other hedge funds are holding VTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventas, Inc. (NYSE:VTR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ventas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventas wasn't on the list.
While Ventas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report